Skip to main content
Erschienen in: Medical Oncology 2/2024

01.02.2024 | Original Paper

Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway

verfasst von: Donglin Sun, Jing Guo, Weifei Liang, Yangxiao Chen, Shuqi Wei, Ai Li, Li Wang, Xiangqiu Chen

Erschienen in: Medical Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Prostate cancer (PCa) is one of the most common malignant tumors that exhibit both chemoresistance and recurrence. SUV39H2 is highly expressed in many types of human tumors, but its role in the development and progression of PCa has never been clarified. The aim of this study is to elucidate the role of SUV39H2 in the development and progression of PCa, its association with the AKT/FOXO signaling pathway, and its potential implications for PCa diagnosis and treatment. SUV39H2 expression was analyzed in The Cancer Genome Atlas (TCGA) and genotype tissue expression pan-cancer data. The TCGA database was evaluated for SUV39H2 enrichment and its correlation to immune cell infiltration. SUV39H2 levels in PCa tissues and control tissues were determined in 30 patients using qPCR and IHC. Clinical relevance was assessed via The Cancer Genome Atlas (TCGA). In vitro assessments including colony formation assays, Western Blot analysis, CCK-8 assays, and flow cytometry were utilized to establish SUV39H2’s contribution to PCa cell growth. The influence of SUV39H2 on PC3 and DU145 cell proliferation was assessed through a cell line-derived xenograft model. Sphere formation assays and qPCR were employed to delineate SUV39H2’s role in PCa stemness and chemosensitivity. In vitro macrophage polarization assays provided insights into SUV39H2’s association with M2 macrophages, while enrichment analysis shed light on its role in FOXO signaling. PCa tissues expressed higher levels of SUV39H2 than normal tissues. By knocking down SUV39H2, PCa cells were made more chemosensitive to docetaxel and cell proliferation and stemness were inhibited. Additionally, SUV39H2 knockdown significantly inhibited in vivo PCa cell growth and inhibited the polarization of macrophages. Furthermore, SUV39H2 was found to regulate AKT/FOXO signaling by increasing Akt and FOXO3a phosphorylation. Our findings highlight SUV39H2’s role in PCa cell apoptosis and chemosensitivity mainly by regulating the AKT/FOXO signaling pathway and suggest that SUV39H2 could be a potential target for PCa diagnosis and treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Zhao K, Li D, Xu W, Ding J, Jiang W, Li M, et al. Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer. Biomaterials. 2017;116:82–94.PubMedCrossRef Zhao K, Li D, Xu W, Ding J, Jiang W, Li M, et al. Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer. Biomaterials. 2017;116:82–94.PubMedCrossRef
3.
Zurück zum Zitat Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harbor Persp Med. 2018;8:a030361.CrossRef Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harbor Persp Med. 2018;8:a030361.CrossRef
4.
Zurück zum Zitat Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA: Cancer J Clin. 2020;70:145–64.PubMed Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA: Cancer J Clin. 2020;70:145–64.PubMed
5.
Zurück zum Zitat Hariri L, Rehman A. Estradiol. Treasure Island: Stat-Pearls Publishing LLC; 2022. Hariri L, Rehman A. Estradiol. Treasure Island: Stat-Pearls Publishing LLC; 2022.
6.
Zurück zum Zitat Peng Y, Dong S, Yang Z, Song Y, Ding J, Hou D, et al. Identification of docetaxel-related biomarkers for prostate cancer. Andrologia. 2021;53:e14079.PubMedCrossRef Peng Y, Dong S, Yang Z, Song Y, Ding J, Hou D, et al. Identification of docetaxel-related biomarkers for prostate cancer. Andrologia. 2021;53:e14079.PubMedCrossRef
7.
Zurück zum Zitat Pérez G, López-Moncada F, Indo S, Torres MJ, Castellón EA, Contreras HR. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells. Oncol Rep. 2021;45:1–12.CrossRef Pérez G, López-Moncada F, Indo S, Torres MJ, Castellón EA, Contreras HR. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells. Oncol Rep. 2021;45:1–12.CrossRef
8.
9.
Zurück zum Zitat Schwarz FM, Schniewind I, Besso MJ, Lange S, Linge A, Patil SG, et al. Plasticity within aldehyde dehydrogenase-positive cells determines prostate cancer radiosensitivity. Mol Cancer Res. 2022;20:794–809.PubMedCrossRef Schwarz FM, Schniewind I, Besso MJ, Lange S, Linge A, Patil SG, et al. Plasticity within aldehyde dehydrogenase-positive cells determines prostate cancer radiosensitivity. Mol Cancer Res. 2022;20:794–809.PubMedCrossRef
10.
Zurück zum Zitat Lee SI, Roney MSI, Park JH, Baek JY, Park J, Kim SK, et al. Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells. Prostate. 2019;79:720–31.PubMedCrossRef Lee SI, Roney MSI, Park JH, Baek JY, Park J, Kim SK, et al. Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells. Prostate. 2019;79:720–31.PubMedCrossRef
11.
Zurück zum Zitat Ren W, Wang D, Li C, Shu T, Zhang W, Fu X. Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/β-catenin signaling. Biomed Pharmacother. 2018;108:467–75.PubMedCrossRef Ren W, Wang D, Li C, Shu T, Zhang W, Fu X. Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/β-catenin signaling. Biomed Pharmacother. 2018;108:467–75.PubMedCrossRef
12.
Zurück zum Zitat Xu P, Cai F, Liu X, Guo L. LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway. Int J Clin Exp Pathol. 2014;7:8480.PubMedPubMedCentral Xu P, Cai F, Liu X, Guo L. LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway. Int J Clin Exp Pathol. 2014;7:8480.PubMedPubMedCentral
13.
Zurück zum Zitat Xiao L, Peng H, Yan M, Chen S. Silencing ACTG1 expression induces prostate cancer epithelial mesenchymal transition through MAPK/ERK signaling pathway. DNA Cell Biol. 2021;40:1445–55.PubMedCrossRef Xiao L, Peng H, Yan M, Chen S. Silencing ACTG1 expression induces prostate cancer epithelial mesenchymal transition through MAPK/ERK signaling pathway. DNA Cell Biol. 2021;40:1445–55.PubMedCrossRef
14.
Zurück zum Zitat Lai W, Zhu W, Xiao C, Li X, Wang Y, Han Y, et al. HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway. Cell Death Dis. 2021;12:583.PubMedPubMedCentralCrossRef Lai W, Zhu W, Xiao C, Li X, Wang Y, Han Y, et al. HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway. Cell Death Dis. 2021;12:583.PubMedPubMedCentralCrossRef
15.
16.
Zurück zum Zitat Haflidadóttir BS, Larne O, Martin M, Persson M, Edsjö A, Bjartell A, et al. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS ONE. 2013;8:e72400.PubMedPubMedCentralCrossRef Haflidadóttir BS, Larne O, Martin M, Persson M, Edsjö A, Bjartell A, et al. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS ONE. 2013;8:e72400.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene. 2007;26:7647–55.PubMedCrossRef Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene. 2007;26:7647–55.PubMedCrossRef
18.
Zurück zum Zitat Yan Y, Huang H. Interplay among PI3K/AKT, PTEN/FOXO and AR signaling in prostate cancer. Adv Exp Med Biol. 2019;1210:319–31.PubMedCrossRef Yan Y, Huang H. Interplay among PI3K/AKT, PTEN/FOXO and AR signaling in prostate cancer. Adv Exp Med Biol. 2019;1210:319–31.PubMedCrossRef
19.
Zurück zum Zitat Wu Y, Sarkissyan M, Vadgama JV. Epigenetics in breast and prostate cancer. In: Cancer epigenetics: risk assessment, diagnosis, treatment, and prognosis. Springer; 2015. p. 425–66.CrossRef Wu Y, Sarkissyan M, Vadgama JV. Epigenetics in breast and prostate cancer. In: Cancer epigenetics: risk assessment, diagnosis, treatment, and prognosis. Springer; 2015. p. 425–66.CrossRef
20.
Zurück zum Zitat Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, Pereira A, Menezes FD, Antunes L, et al. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer. 2014;21:51–61.PubMedCrossRef Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, Pereira A, Menezes FD, Antunes L, et al. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr Relat Cancer. 2014;21:51–61.PubMedCrossRef
22.
Zurück zum Zitat Piao L, Nakakido M, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R. Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins. Oncotarget. 2016;7:22846.PubMedPubMedCentralCrossRef Piao L, Nakakido M, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R. Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins. Oncotarget. 2016;7:22846.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Askew EB, Bai S, Parris AB, Minges JT, Wilson EM. Androgen receptor regulation by histone methyltransferase suppressor of variegation 3–9 homolog 2 and Melanoma antigen-A11. Mol Cell Endocrinol. 2017;443:42–51.PubMedCrossRef Askew EB, Bai S, Parris AB, Minges JT, Wilson EM. Androgen receptor regulation by histone methyltransferase suppressor of variegation 3–9 homolog 2 and Melanoma antigen-A11. Mol Cell Endocrinol. 2017;443:42–51.PubMedCrossRef
24.
Zurück zum Zitat Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, Yuan W, Berk M, et al. H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Proc Natl Acad Sci. 2022;119:e2114324119.PubMedPubMedCentralCrossRef Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, Yuan W, Berk M, et al. H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Proc Natl Acad Sci. 2022;119:e2114324119.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Hung S-Y, Lin H-H, Yeh K-T, Chang J-G. Histone-modifying genes as biomarkers in hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7:2496.PubMedPubMedCentral Hung S-Y, Lin H-H, Yeh K-T, Chang J-G. Histone-modifying genes as biomarkers in hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7:2496.PubMedPubMedCentral
26.
Zurück zum Zitat Miao Y, Liu G, Liu L. Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma. Cancer Cell Int. 2021;21:1–12.CrossRef Miao Y, Liu G, Liu L. Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma. Cancer Cell Int. 2021;21:1–12.CrossRef
27.
Zurück zum Zitat Reyes DA, Sarría VMS, Salazar-Viedma M, D’Afonseca V. Histone methyltransferases useful in gastric cancer research. Cancer Informatics. 2021;20:11769351211039862.PubMedPubMedCentralCrossRef Reyes DA, Sarría VMS, Salazar-Viedma M, D’Afonseca V. Histone methyltransferases useful in gastric cancer research. Cancer Informatics. 2021;20:11769351211039862.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Shuai W, Wu J, Chen S, Liu R, Ye Z, Kuang C, et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. Cancer Lett. 2018;422:56–69.PubMedCrossRef Shuai W, Wu J, Chen S, Liu R, Ye Z, Kuang C, et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. Cancer Lett. 2018;422:56–69.PubMedCrossRef
29.
Zurück zum Zitat Yoon K-A, Hwangbo B, Kim I-J, Park S, Kim HS, Kee HJ, et al. Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis. 2006;27:2217–22.PubMedCrossRef Yoon K-A, Hwangbo B, Kim I-J, Park S, Kim HS, Kee HJ, et al. Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis. 2006;27:2217–22.PubMedCrossRef
30.
Zurück zum Zitat Zheng Y, Li B, Wang J, Xiong Y, Wang K, Qi Y, et al. Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma. Clin Epigenetics. 2018;10:1–11.CrossRef Zheng Y, Li B, Wang J, Xiong Y, Wang K, Qi Y, et al. Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma. Clin Epigenetics. 2018;10:1–11.CrossRef
31.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25:402–8.PubMedCrossRef
32.
Zurück zum Zitat Hu Y, Zhang H, Xie N, Liu D, Jiang Y, Liu Z, et al. Bcl-3 promotes TNF-induced hepatocyte apoptosis by regulating the deubiquitination of RIP1. Cell Death Differ. 2022;29:1176–86.PubMedCrossRef Hu Y, Zhang H, Xie N, Liu D, Jiang Y, Liu Z, et al. Bcl-3 promotes TNF-induced hepatocyte apoptosis by regulating the deubiquitination of RIP1. Cell Death Differ. 2022;29:1176–86.PubMedCrossRef
33.
Zurück zum Zitat Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping H, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci. 2020;16:1121.PubMedPubMedCentralCrossRef Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping H, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci. 2020;16:1121.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Ye D, Liu H, Zhao G, Chen A, Jiang Y, Hu Y, et al. LncGMDS-AS1 promotes the tumorigenesis of colorectal cancer through HuR-STAT3/Wnt axis. Cell Death Dis. 2023;14:165.PubMedPubMedCentralCrossRef Ye D, Liu H, Zhao G, Chen A, Jiang Y, Hu Y, et al. LncGMDS-AS1 promotes the tumorigenesis of colorectal cancer through HuR-STAT3/Wnt axis. Cell Death Dis. 2023;14:165.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Jia G, Wang X, Wu W, Zhang Y, Chen S, Zhao J, et al. LXA4 enhances prostate cancer progression by facilitating M2 macrophage polarization via inhibition of METTL3. Int Immunopharmacol. 2022;107:108586.PubMedCrossRef Jia G, Wang X, Wu W, Zhang Y, Chen S, Zhao J, et al. LXA4 enhances prostate cancer progression by facilitating M2 macrophage polarization via inhibition of METTL3. Int Immunopharmacol. 2022;107:108586.PubMedCrossRef
36.
Zurück zum Zitat Tsirmoula S, Dimas K, Hatziapostolou M, Lamprou M, Ravazoula P, Papadimitriou E. Implications of pleiotrophin in human PC 3 prostate cancer cell growth in vivo. Cancer Sci. 2012;103:1826–32.PubMedPubMedCentralCrossRef Tsirmoula S, Dimas K, Hatziapostolou M, Lamprou M, Ravazoula P, Papadimitriou E. Implications of pleiotrophin in human PC 3 prostate cancer cell growth in vivo. Cancer Sci. 2012;103:1826–32.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Zhang K, Waxman DJ. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer. 2010;9:1–13.CrossRef Zhang K, Waxman DJ. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer. 2010;9:1–13.CrossRef
39.
Zurück zum Zitat Skvortsov S, Skvortsova I-I, Tang DG, Dubrovska A. Concise review: prostate cancer stem cells: current understanding. Stem Cells. 2018;36:1457–74.PubMedCrossRef Skvortsov S, Skvortsova I-I, Tang DG, Dubrovska A. Concise review: prostate cancer stem cells: current understanding. Stem Cells. 2018;36:1457–74.PubMedCrossRef
40.
Zurück zum Zitat Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090.PubMedCrossRef Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090.PubMedCrossRef
41.
Zurück zum Zitat Angeles AK, Heckmann D, Flosdorf N, Duensing S, Sültmann H. The ERG-regulated LINC00920 promotes prostate cancer cell survival via the 14-3-3ϵ–FOXO pathway. Mol Cancer Res. 2020;18:1545–59.PubMedCrossRef Angeles AK, Heckmann D, Flosdorf N, Duensing S, Sültmann H. The ERG-regulated LINC00920 promotes prostate cancer cell survival via the 14-3-3ϵ–FOXO pathway. Mol Cancer Res. 2020;18:1545–59.PubMedCrossRef
42.
Zurück zum Zitat Wang S, Xu G, Chao F, Zhang C, Han D, Chen G. HNRNPC promotes proliferation, metastasis and predicts prognosis in prostate cancer. Cancer Manag Res. 2021;13:7263–76.PubMedPubMedCentralCrossRef Wang S, Xu G, Chao F, Zhang C, Han D, Chen G. HNRNPC promotes proliferation, metastasis and predicts prognosis in prostate cancer. Cancer Manag Res. 2021;13:7263–76.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat García-Cao M, O’Sullivan R, Peters AH, Jenuwein T, Blasco MA. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet. 2004;36:94–9.PubMedCrossRef García-Cao M, O’Sullivan R, Peters AH, Jenuwein T, Blasco MA. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet. 2004;36:94–9.PubMedCrossRef
45.
Zurück zum Zitat Nielsen SJ, Schneider R, Bauer U-M, Bannister AJ, Morrison A, O’Carroll D, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature. 2001;412:561–5.PubMedCrossRef Nielsen SJ, Schneider R, Bauer U-M, Bannister AJ, Morrison A, O’Carroll D, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature. 2001;412:561–5.PubMedCrossRef
46.
Zurück zum Zitat Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–6.PubMedCrossRef Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–6.PubMedCrossRef
47.
48.
Zurück zum Zitat Dobosy JR, Roberts JLW, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol. 2007;177:822–31.PubMedCrossRef Dobosy JR, Roberts JLW, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol. 2007;177:822–31.PubMedCrossRef
49.
Zurück zum Zitat Perry AS, Watson RWG, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol. 2010;7:668–80.PubMedCrossRef Perry AS, Watson RWG, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol. 2010;7:668–80.PubMedCrossRef
50.
Zurück zum Zitat Leão R, Domingos C, Figueiredo A, Hamilton R, Tabori U, Castelo-Branco P. Cancer stem cells in prostate cancer: implications for targeted therapy. Urol Int. 2017;99:125–36.PubMedCrossRef Leão R, Domingos C, Figueiredo A, Hamilton R, Tabori U, Castelo-Branco P. Cancer stem cells in prostate cancer: implications for targeted therapy. Urol Int. 2017;99:125–36.PubMedCrossRef
51.
52.
Zurück zum Zitat Obeng E. Apoptosis (programmed cell death) and its signals—a review. Braz J Biol. 2020;81:1133–43.CrossRef Obeng E. Apoptosis (programmed cell death) and its signals—a review. Braz J Biol. 2020;81:1133–43.CrossRef
53.
Zurück zum Zitat Li X, Liu K, Zhou W, Jiang Z. MiR-155 targeting FoxO3a regulates oral cancer cell proliferation, apoptosis, and DDP resistance through targeting FoxO3a. Cancer Biomark. 2020;27:105–11.PubMedCrossRef Li X, Liu K, Zhou W, Jiang Z. MiR-155 targeting FoxO3a regulates oral cancer cell proliferation, apoptosis, and DDP resistance through targeting FoxO3a. Cancer Biomark. 2020;27:105–11.PubMedCrossRef
54.
Zurück zum Zitat Emre Kızıl H, Gür C, Ayna A, Darendelioğlu E, Küçükler S, Sağ S. Contribution of oxidative stress, apoptosis, endoplasmic reticulum stress and autophagy pathways to the ameliorative effects of hesperidin in NaF-induced testicular toxicity. Chem Biodivers. 2023;20:e202200982.PubMedCrossRef Emre Kızıl H, Gür C, Ayna A, Darendelioğlu E, Küçükler S, Sağ S. Contribution of oxidative stress, apoptosis, endoplasmic reticulum stress and autophagy pathways to the ameliorative effects of hesperidin in NaF-induced testicular toxicity. Chem Biodivers. 2023;20:e202200982.PubMedCrossRef
55.
Zurück zum Zitat Kızıl HE, Caglayan C, Darendelioğlu E, Ayna A, Gür C, Kandemir FM, et al. Morin ameliorates methotrexate-induced hepatotoxicity via targeting Nrf2/HO-1 and Bax/Bcl2/caspase-3 signaling pathways. Mol Biol Rep. 2023;50:3479–88.PubMedCrossRef Kızıl HE, Caglayan C, Darendelioğlu E, Ayna A, Gür C, Kandemir FM, et al. Morin ameliorates methotrexate-induced hepatotoxicity via targeting Nrf2/HO-1 and Bax/Bcl2/caspase-3 signaling pathways. Mol Biol Rep. 2023;50:3479–88.PubMedCrossRef
56.
Zurück zum Zitat Liu Y, Wang Y, Li X, Jia Y, Wang J, Ao X. FOXO3a in cancer drug resistance. Cancer Lett. 2022;540:215724.PubMedCrossRef Liu Y, Wang Y, Li X, Jia Y, Wang J, Ao X. FOXO3a in cancer drug resistance. Cancer Lett. 2022;540:215724.PubMedCrossRef
57.
Zurück zum Zitat Varışlı B, Darendelioğlu E, Caglayan C, Kandemir FM, Ayna A, Genç A, et al. Hesperidin attenuates oxidative stress, inflammation, apoptosis, and cardiac dysfunction in sodium fluoride-Induced cardiotoxicity in rats. Cardiovasc Toxicol. 2022;22:727–35.PubMedCrossRef Varışlı B, Darendelioğlu E, Caglayan C, Kandemir FM, Ayna A, Genç A, et al. Hesperidin attenuates oxidative stress, inflammation, apoptosis, and cardiac dysfunction in sodium fluoride-Induced cardiotoxicity in rats. Cardiovasc Toxicol. 2022;22:727–35.PubMedCrossRef
58.
Zurück zum Zitat Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–86.PubMedPubMedCentralCrossRef Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–86.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, et al. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth. Cancer Discov. 2018;8:764–79.PubMedCrossRef Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, et al. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with Pten loss to accelerate progression and castration-resistant growth. Cancer Discov. 2018;8:764–79.PubMedCrossRef
Metadaten
Titel
Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway
verfasst von
Donglin Sun
Jing Guo
Weifei Liang
Yangxiao Chen
Shuqi Wei
Ai Li
Li Wang
Xiangqiu Chen
Publikationsdatum
01.02.2024
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2024
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-023-02252-x

Weitere Artikel der Ausgabe 2/2024

Medical Oncology 2/2024 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.